|
PF-48378 |
CANESTEN 1% Aerosol (simple/solución) |
2018-03-05 |
|
|
Alemania
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-48380 |
CANESTEN 1% Solución Tópica |
2018-03-06 |
|
|
Alemania
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-57824 |
NITROPRUSIATO DE SODIO Kwality 50 mg Polvo liofilizado para solución inyectable |
2025-01-23 |
|
Kwality Pharmaceuticals Limited |
India
|
Repremedh Representaciones Médicas Hospitalarias |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-57909 |
ADENOSINA Kwality 3 mg/ mL Solución inyectable |
2025-02-11 |
|
Kwality Pharmaceuticals Limited |
India
|
Repremedh Representaciones Médicas Hospitalarias |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-58719 |
LIDOCAINA Kwality 2% Solución inyectable |
2025-10-27 |
|
Kwality Pharmaceuticals Limited |
India
|
A R Pharma |
Repremedh Representaciones Médicas Hospitalarias |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-59124 |
ACICLOVIR Kwality 250 mg Polvo liofilizado para solución inyectable |
2026-03-04 |
|
Kwality Pharmaceuticals Limited |
India
|
A R Pharma |
Repremedh Representaciones Médicas Hospitalarias |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-59225 |
GANCICLOVIR Kwality 500 mg Polvo liofilizado para uso parenteral |
2026-03-26 |
|
Kwality Pharmaceuticals Limited |
India
|
Repremedh Representaciones Médicas Hospitalarias |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-60136 |
PROPOFOL Vijayasudha 10 mg/ mL Emulsión inyectable |
2026-09-30 |
|
Vijayasudha Pharmaceuticals Pvt.Ltd. |
India
|
Cisa |
Dispromed |
VMG Healthcare Products |
Wensur |
Arael de Centro América |
Droguería Colón |
LCJ |
La Botica |
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-60270 |
ESOMEPRAZOL Kwality 40 mg Polvo liofilizado para uso parenteral |
2026-10-26 |
|
Kwality Pharmaceuticals Limited |
India
|
REPREMEDH |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-54985 |
VINCRISTINA SULFATO KRISHPAR 1mg / mL Solución Inyectable |
2023-03-05 |
|
Asmoh Laboratories Limited. |
India
|
Krishpar Healthcare |
Medicalsa |
Centrino Pharma |
Repremedh Representaciones Médicas Hospitalarias |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|